Lung cancer combo aims to clear cancer DNA

NCT ID NCT07264673

Recruiting now Disease control Sponsor: Fondazione Ricerca Traslazionale Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding OSE2101 (TEDOPI®) to standard maintenance therapy with cemiplimab can better clear cancer DNA from the blood in people with advanced non-small cell lung cancer. The study enrolls 160 participants who have a specific immune type (HLA-A2 positive) and have not progressed after initial chemo-immunotherapy. The main goal is to see if the combination increases ctDNA clearance rates compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab and OSE2101 (TEDOPI®)
What this could lead to: If successful, this combination could improve ctDNA clearance and potentially delay cancer progression in NSCLC patients.
What could go wrong: This is an early phase II trial with only 160 participants, so results may not apply broadly. The treatment may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITING

Roma, RM, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.